The short answer
Evaluation may include excisional or core biopsy, immunophenotyping, molecular studies, imaging, blood tests, and selected marrow or CNS assessment. Each result should answer a specific diagnostic, risk, or treatment question.
Evaluation may include excisional or core biopsy, immunophenotyping, molecular studies, imaging, blood tests, and selected marrow or CNS assessment.
Planning may depend on pathology subtype, stage, tumor sites, molecular findings, organ function, fitness, and prior treatment.
A result can be diagnostic, prognostic, predictive, or useful for monitoring—and these are not identical roles.
Ask which results are confirmed and which remain pending.
Choose how you want to understand this
The full explanation.
What the biopsy shows
DLBCL is diagnosed from a lymph-node or tissue biopsy. An excisional biopsy, which removes the whole node, confirms the diagnosis correctly about 98% of the time. A core needle biopsy, a thinner sample, still works well and confirms the diagnosis about 92% of the time. Either way, a hematopathologist, a specialist in blood and lymph tissue, should review the slides. This matters because DLBCL can look similar to other lymphomas under a basic exam.
Your report will likely mention CD20, a protein on the surface of the lymphoma cells. Nearly all DLBCL cases are CD20-positive, which is what allows treatment with CD20-targeted antibody drugs. The pathologist may also test whether the cancer looks and behaves more like a germinal-center cell or an activated B-cell. This is called cell-of-origin testing, and it can affect prognosis.
Why MYC and BCL2 findings matter
Some DLBCL cells have extra copies or rearrangements of the MYC and BCL2 genes, sometimes both together. This combination is linked to a harder-to-treat disease. It may push your team toward a more intensive chemotherapy regimen instead of the usual first choice. Ask whether your tissue was tested for these changes.
The International Prognostic Index
Doctors often calculate a risk score called the IPI. It adds up five factors. These are age, stage, a fitness measure called performance status, a blood test called LDH, and how many areas outside the lymph nodes are involved. Higher scores are linked to lower five-year survival in large studies. Rates range from about 96% in the lowest-risk group to about 33% in the highest-risk group. The IPI is a planning tool, not a prediction for one individual.
How results connect to treatment
The standard first treatment for DLBCL is a combination called R-CHOP: rituximab plus four chemotherapy drugs. Some people, particularly those with certain high-risk features, may instead get Pola-R-CHP, which swaps in a drug called polatuzumab vedotin. A related but distinct fast-growing lymphoma is called primary mediastinal B-cell lymphoma. It often responds well to a regimen called dose-adjusted R-EPOCH.
If DLBCL comes back, or does not respond to first treatment, options include different chemotherapy combinations. Another option is CD19-directed CAR T-cell therapy, which uses your own reprogrammed immune cells. NCI reports that in trials involving people with large cell lymphoma, more than 30% of participants were alive with no evidence of cancer five years after this treatment.
What's still pending
Cell-of-origin testing, MYC and BCL2 studies, and other marker panels can take one to two weeks. Ask whether your treatment start date can wait for these results, since they can change which regimen your team recommends.
What to ask your team
- Was my tissue reviewed by a hematopathologist experienced in lymphoma?
- What is my cell-of-origin result, and were MYC and BCL2 tested?
- What is my IPI score, and how does it shape the plan?
- Is R-CHOP the recommended first treatment, or does something else fit better?
- If this comes back, what would the next options be?
Sources
Words to know
Tap any term to see what it means.
Common questions
Which biopsy is used to diagnose DLBCL?
A lymph-node or tissue biopsy. An excisional biopsy, which removes the whole node, confirms the diagnosis correctly about 98% of the time, and a core needle biopsy, a thinner sample, still works well at about 92%. Either way a hematopathologist, a specialist in blood and lymph tissue, should review the slides, because DLBCL can look similar to other lymphomas under a basic exam.
What is CD20, and why is it on my report?
It is a protein on the surface of the lymphoma cells. Nearly all DLBCL cases are CD20-positive, which is what allows treatment with CD20-targeted antibody drugs.
Why do MYC and BCL2 matter?
Some DLBCL cells have extra copies or rearrangements of the MYC and BCL2 genes, sometimes both together. That combination is linked to harder-to-treat disease, and it may push your team toward a more intensive chemotherapy regimen instead of the usual first choice. Ask whether your tissue was tested for these changes.
What is the IPI?
The International Prognostic Index, a risk score that adds up five factors: age, stage, a fitness measure called performance status, a blood test called LDH, and how many areas outside the lymph nodes are involved. Higher scores are linked to lower five-year survival in large studies, from about 96% in the lowest-risk group to about 33% in the highest. It is a planning tool, not a prediction for one individual.
What is the standard first treatment?
R-CHOP, which is rituximab plus four chemotherapy drugs. Some people, particularly those with certain high-risk features, may instead get Pola-R-CHP, which swaps in a drug called polatuzumab vedotin. If DLBCL comes back or does not respond to first treatment, options include different chemotherapy combinations and CD19-directed CAR T-cell therapy, which uses your own reprogrammed immune cells.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Your next step
Turn this guide into a short list for your care team.
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Sources last checked: 2026-07-22 what this meansLast updated: 2026-08-17Next planned review: 2027-07-22
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share